Riix halkan haddii kani yahay war-saxaafadeedkaaga!

Daraasad Cusub Oo Tallaalka Daawaynta Kansarka Oo Lagu Dhawaaqay Shiinaha

Written by editor

Innovent Biologics, Inc. NeoCura), oo ah hormuudka AI-awood u leh RNA saxda ah ee daawada biotech ee ay ka go'an tahay inay dhisto madal dawada hal-abuurka leh ee RNA ee ugu sareysa, maanta waxay si wadajir ah u shaaciyeen inay galeen heshiis iskaashi istiraatiiji ah si ay u fuliyaan daraasad caafimaad gudaha Shiinaha oo ku saabsan daaweynta isku dhafka ah ee sintilimab laga bilaabo Innovent iyo tallaalka neoantigen shaqsiyeysan ee NEO_PLIN2101 ee NeoCura.

Print Friendly, PDF & Email

Innovent waxay iskaashi la samayn doontaa NeoCura ee Shiinaha si ay u qiimeeyaan badbaadada, farmasokinetics, pharmacodynamics iyo waxtarka hordhaca ah ee daaweynta isku dhafka ah iyadoo la adeegsanayo sintilimab ka Innovent iyo NEO_PLIN2101 oo ka socda NeoCura ee bukaannada kansarka, si loo hormariyo horumarinta kiliinikada isku dhafka immunotherapy ee burooyinka adag ee badan Codsiga Dawada Cusub ee Baarista (IND) ee Maamulka Alaabooyinka Caafimaadka Qaranka (NMPA) mustaqbalka dhow.

Dr. Liu Yongjun, Madaxweynaha Innovent, ayaa yiri: "Waxaan aad ula dhacsanahay NeoCura's dhuunta R & D ee kala duwan iyo kooxda cilmi-baarista caalamiga ah, waxaanan ku faraxsanahay inaan galno iskaashigan istaraatiijiyadeed si aan u sahamino qiimaha kiliinikada ee sintilimab oo ay weheliso tallaalada neoantigen ee burooyinka adag . Innovent waxay leedahay dhuumo adag oo awood u leh xagga difaaca jirka iyo bayoolajiga kansarka. Hadda, waxaanu haynaa shan dawooyin cusub oo la ansixiyey oo laga bilaabay Shiinaha waxaanan yeelan doonaa in ka badan 10 dawooyin cusub oo la bilaabayo 2-3 sano ee soo socota. Qalabkayaga si buuxda isku dhafan ayaa urursaday R&D xooggan, kobcinta kiliinikada iyo awoodaha ganacsi waxayna ku habboon tahay la-hawlgalayaasha gudaha iyo dibedda. Waxaan sidoo kale rajeyneynaa inaan sii sahamno fursadaha cusub ee ballaarinta calaamadaha iyo kor u qaadista waxtarka daaweynta sintilimab oo ay weheliso daawaynta cusub. Waxaan rajaynaynaa wada shaqayn balaadhan oo qoto dheer oo dhex marta labada dhinac mustaqbalka. "

Dr. Wang Yi, aasaasaha NeoCura, wuxuu yiri: "Waqtigan xaadirka ah, tallaalada neoantigen waa hab kacaan oo daweyn ah oo soo baxaya adduunka oo dhan. NeoCura waxa ay diiradda saareysay R&D ee tallaallada neoantigen ee burooyinka tan iyo markii la aasaasay, iyadoo rajeyneysa in ay ka gudubto caqabadaha jira daweynta difaaca jirka ee daaweynta burooyinka adag iyada oo loo marayo adeegsiga tignoolajiyada cusub. Wadashaqeynta Innovent waxay ka ciyaari doontaa doorka isdhexgalka ee tallaalada neoantigen ee shakhsi ahaaneed iyo daawooyinka monoclonal antibody waxayna si wadajir ah u sahamiyaan saameynta kiliinikada ee daaweynta isku dhafka ah ee daaweynta burooyinka adag, taas oo la filayo inay wanaajiso heerka jawaabta ujeedada kansarka immunotherapy iyo keeni fursado cusub. loogu talagalay hababka isku dhafka ah ee kansarka."

Print Friendly, PDF & Email

War ku saabsan qoraaga

editor

Tifatiraha guud waa Linda Hohnholz.

Leave a Comment